![Emilia Bulaevsky Zychlinsky](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Emilia Bulaevsky Zychlinsky
Operationeel Directeur bij Exai Bio, Inc.
Profiel
Emilia Bulaevsky Zychlinsky is currently the Executive Vice President-Operations at Exai Bio, Inc. She previously worked as the Senior VP-Regulatory Affairs & Quality Assurance at Standard BioTools, Inc. and as the Vice President-Operations, Research & Development at Minaris Medical America, Inc. From 2011 to 2016, she was the Chief Technical Officer & Executive Vice President at Diadexus, Inc. Dr. Zychlinsky holds a doctorate degree from Stanford University and an undergraduate degree from Instituto Politecnico Nacional.
Actieve functies van Emilia Bulaevsky Zychlinsky
Bedrijven | Functie | Begin |
---|---|---|
Exai Bio, Inc.
![]() Exai Bio, Inc. Packaged SoftwareTechnology Services Exai Bio, Inc. is an American next-generation liquid biopsy company founded by Hani Goodarzi, Babak Alipanahi, and Patrick Arensdorf. The company's mission is to enable early detection, accurate diagnosis, personalized and targeted treatment, and ultimately cure of cancer. Exai Bio's proprietary RNA- and AI-based liquid biopsy technology delivers clinical insights into cancer biology to enable the earliest and most accurate diagnosis of cancer. Patrick Arensdorf has been the CEO since incorporation. | Operationeel Directeur | 02-02-2023 |
Eerdere bekende functies van Emilia Bulaevsky Zychlinsky
Bedrijven | Functie | Einde |
---|---|---|
DIADEXUS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-04-2016 |
Minaris Medical America, Inc.
![]() Minaris Medical America, Inc. Medical SpecialtiesHealth Technology Minaris Medical America, Inc. manufactures the CLA and OPTIGEN Allergy Tests, in vitro diagnostic tests and alternative to skin tests. It serves the medical community through its Allos Reference Laboratory. The firm’s products include the CLA Allergen-Specific IgE Assay, theOPTIGEN Allergen-Specific IgE Assay, CLA-1 Luminometer In Vitro Allergy Diagnostic System and AP 720S Semi-Automated In Vitro Allergy Diagnostic System. The company is headquartered in Mountain View, CA. | Hoofd Techniek/Wetenschap/O&O | - |
STANDARD BIOTOOLS INC. | Algemeen Adviseur | - |
Opleiding van Emilia Bulaevsky Zychlinsky
Stanford University | Doctorate Degree |
Instituto Politecnico Nacional | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
STANDARD BIOTOOLS INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Diadexus, Inc.
![]() Diadexus, Inc. BiotechnologyHealth Technology Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio intends to treat cardiovascular diseases. The company was founded on November 27, 1995 and is headquartered in South San Francisco, CA. | Health Technology |
Minaris Medical America, Inc.
![]() Minaris Medical America, Inc. Medical SpecialtiesHealth Technology Minaris Medical America, Inc. manufactures the CLA and OPTIGEN Allergy Tests, in vitro diagnostic tests and alternative to skin tests. It serves the medical community through its Allos Reference Laboratory. The firm’s products include the CLA Allergen-Specific IgE Assay, theOPTIGEN Allergen-Specific IgE Assay, CLA-1 Luminometer In Vitro Allergy Diagnostic System and AP 720S Semi-Automated In Vitro Allergy Diagnostic System. The company is headquartered in Mountain View, CA. | Health Technology |
Exai Bio, Inc.
![]() Exai Bio, Inc. Packaged SoftwareTechnology Services Exai Bio, Inc. is an American next-generation liquid biopsy company founded by Hani Goodarzi, Babak Alipanahi, and Patrick Arensdorf. The company's mission is to enable early detection, accurate diagnosis, personalized and targeted treatment, and ultimately cure of cancer. Exai Bio's proprietary RNA- and AI-based liquid biopsy technology delivers clinical insights into cancer biology to enable the earliest and most accurate diagnosis of cancer. Patrick Arensdorf has been the CEO since incorporation. | Technology Services |